glp-1 weight loss marketing Eating disorder groups are sounding alarms about the rapid rollout of treatments, saying vulnerable people are being deliberately targeted by weight-loss marketing. The Australia and New Zealand Academy for Eating Disorders Hot take: both sides are

Some patients began feeling this potentially disabling joint pain within just one day of starting DPP-4 treatment, while others developed joint pain years after beginning treatment

Retatrutide , a triple agonist targeting GLP-1, GIP, and glucagon receptors, has shown even more dramatic weight loss in clinical trials, with some participants losing over 25% of their body weight

In contrast, treating obesity with GLP-1RA decreases cardiovascular risk and the possible mechanisms of cardioprotection achieved by this class of drugs are discussed

These injections can boost energy levels, improve cognitive function, and support overall health